DK478886A - Monoklonalt murinantistof egnet til genkendelse af brysttumorer og immunogenkendelsesmiddel omfattende samme samt fremgangsmaade til genkendelse af samme - Google Patents

Monoklonalt murinantistof egnet til genkendelse af brysttumorer og immunogenkendelsesmiddel omfattende samme samt fremgangsmaade til genkendelse af samme Download PDF

Info

Publication number
DK478886A
DK478886A DK478886A DK478886A DK478886A DK 478886 A DK478886 A DK 478886A DK 478886 A DK478886 A DK 478886A DK 478886 A DK478886 A DK 478886A DK 478886 A DK478886 A DK 478886A
Authority
DK
Denmark
Prior art keywords
recognition
same
monoclonal
murinary
immunogeneous
Prior art date
Application number
DK478886A
Other languages
English (en)
Other versions
DK478886D0 (da
Inventor
David Barratt Ring
Arthur Edward Frankel
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK478886D0 publication Critical patent/DK478886D0/da
Publication of DK478886A publication Critical patent/DK478886A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Navigation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK478886A 1985-10-07 1986-10-07 Monoklonalt murinantistof egnet til genkendelse af brysttumorer og immunogenkendelsesmiddel omfattende samme samt fremgangsmaade til genkendelse af samme DK478886A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78507685A 1985-10-07 1985-10-07
US06/786,948 US4938948A (en) 1985-10-07 1985-10-11 Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies

Publications (2)

Publication Number Publication Date
DK478886D0 DK478886D0 (da) 1986-10-07
DK478886A true DK478886A (da) 1987-04-08

Family

ID=27120360

Family Applications (1)

Application Number Title Priority Date Filing Date
DK478886A DK478886A (da) 1985-10-07 1986-10-07 Monoklonalt murinantistof egnet til genkendelse af brysttumorer og immunogenkendelsesmiddel omfattende samme samt fremgangsmaade til genkendelse af samme

Country Status (13)

Country Link
US (1) US4938948A (da)
EP (1) EP0220858B1 (da)
JP (3) JP2968474B2 (da)
AT (1) ATE85652T1 (da)
AU (1) AU6356986A (da)
CA (1) CA1338706C (da)
DE (1) DE3687736T2 (da)
DK (1) DK478886A (da)
ES (1) ES2053440T3 (da)
FI (1) FI864037A7 (da)
IL (1) IL80231A (da)
NO (1) NO863974L (da)
NZ (1) NZ217829A (da)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
AU613590B2 (en) * 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US7255851B2 (en) * 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
DE10141937A1 (de) * 2001-08-28 2003-03-27 Alfred Schmidt Markierung der Aromatase
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
EP1501855A4 (en) * 2002-03-21 2006-02-22 Sagres Discovery Inc NEW COMPOSITIONS AND METHODS FOR CANCER
US6916474B2 (en) 2002-07-15 2005-07-12 Board Of Regents, The University Of Texas System Antibodies with increased affinities for anthrax antigens
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP1592708A2 (en) 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
CN1925871A (zh) * 2004-01-27 2007-03-07 南加州大学 聚合物结合的抗体癌症治疗剂
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP5307397B2 (ja) 2004-09-18 2013-10-02 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
EP3796003A1 (en) 2005-04-04 2021-03-24 Biogen MA Inc. Methods for evaluating an immune response to a therapeutic agent
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
US8124351B2 (en) 2005-11-18 2012-02-28 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
WO2008067547A2 (en) 2006-11-30 2008-06-05 Research Development Foundation Improved immunoglobulin libraries
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
AU2008247819B2 (en) 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
CA2711499C (en) 2008-01-10 2018-09-25 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US20100135904A1 (en) 2008-11-07 2010-06-03 Research Development Foundation Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
US20110287088A1 (en) 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
BR112014003315A2 (pt) 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
HK1207970A1 (en) 2012-05-10 2016-02-19 Massachusetts Institute Of Technology Agents for influenza neutralization
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
WO2014127211A1 (en) 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
PT3524617T (pt) 2013-03-15 2023-07-12 Gladiator Biosciences Inc Domínios gla como agentes terapêuticos
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
WO2014144666A2 (en) 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
CA2965327C (en) 2013-11-08 2023-05-09 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
US10059775B2 (en) 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
DK3140653T3 (da) 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
KR102485788B1 (ko) 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP6724023B2 (ja) 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
CA2977499C (en) 2015-02-25 2023-10-03 Vanderbilt University Antibody-mediated neutralization of marburg virus
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
JP6987068B2 (ja) 2015-11-09 2021-12-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 癌マーカーおよび治療標的としてのグリピカン２
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
SG11201804648RA (en) 2015-12-04 2018-06-28 Univ Texas Slc45a2 peptides for immunotherapy
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
KR102418372B1 (ko) 2016-03-29 2022-07-08 주식회사 에스티큐브 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
JP7194595B2 (ja) 2016-07-01 2022-12-22 ザ ジェネラル ホスピタル コーポレイション グランザイムｂを指向するイメージングおよび治療
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
EP3534953A4 (en) 2016-11-02 2020-10-07 Vanderbilt University ANTIBODIES AGAINST HUMAN ZIKA VIRUS AND THEIR USE PROCEDURES
US11241511B2 (en) 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
EP3576758A4 (en) 2017-01-31 2020-12-09 Vanderbilt University GENERATION OF IGE MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN ALLERGENS AND HELMINTHS FOR DIAGNOSTIC AND THERAPEUTIC USE
US11583588B2 (en) 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
SG11202001535RA (en) 2017-09-05 2020-03-30 Gladiator Biosciences Inc Method of targeting exosomes
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
CN111868039A (zh) 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
WO2019075097A1 (en) 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
EP3735589A2 (en) 2018-01-05 2020-11-11 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2020056077A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
WO2020092969A1 (en) 2018-11-02 2020-05-07 Oklahoma Medical Research Foundation Monoclonal antibodies to eltd1 and uses thereof
JP7478149B2 (ja) 2018-11-28 2024-05-02 オレゴン ヘルス アンド サイエンス ユニバーシティー 治療用第ｘｉｉ因子抗体
WO2020167989A1 (en) 2019-02-13 2020-08-20 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
CN120484131A (zh) 2019-07-19 2025-08-15 费城儿童医院 包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
JP7644087B2 (ja) 2019-07-26 2025-03-11 ヴァンダービルト ユニバーシティ エンテロウイルスｄ６８に対するヒトモノクローナル抗体
CN114729045B (zh) 2019-09-26 2025-09-09 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
US12595304B2 (en) 2019-10-09 2026-04-07 Stcube & Co., Inc. Antibodies specific to glycosylated LAG3 and methods of use thereof
US20210277092A1 (en) 2020-02-11 2021-09-09 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
EP4255451A4 (en) 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
TW202302155A (zh) 2021-03-08 2023-01-16 美商伊繆諾金公司 用於增加靶向ａｄａｍ９之免疫結合物治療癌症之功效的方法
JP2024536133A (ja) 2021-09-29 2024-10-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗ｈｓｐ７０抗体およびその治療的使用
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
TW202405011A (zh) 2022-04-01 2024-02-01 美國德州系統大學評議委員會 針對人類pd-l1及pd-l2之雙重特異性抗體及其使用方法
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
EP4573553A1 (en) 2022-08-15 2025-06-25 ABSCI Corporation Quantitative affinity activity specific cell enrichment
KR20250160358A (ko) 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
WO2024213640A1 (en) 2023-04-11 2024-10-17 Sterling Ip Pte. Ltd. Inhibition of: stroma/cancer cell cross-talk &/or stroma generated resistance to treatment
WO2026044000A1 (en) 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
EP0155938A1 (en) * 1983-09-28 1985-10-02 Summa Medical Corporation Lectin composition and method for diagnosis of cancer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0160446B1 (en) * 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Breast tumor-associated antigen and monoclonal antibodies specific thereto
US4695538A (en) * 1984-06-01 1987-09-22 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Also Published As

Publication number Publication date
JPH08266273A (ja) 1996-10-15
EP0220858B1 (en) 1993-02-10
ES2053440T3 (es) 1994-08-01
JP2000000092A (ja) 2000-01-07
JP2968474B2 (ja) 1999-10-25
JP2000000091A (ja) 2000-01-07
DE3687736T2 (de) 1993-05-27
FI864037A0 (fi) 1986-10-06
FI864037L (fi) 1987-04-08
NZ217829A (en) 1989-06-28
FI864037A7 (fi) 1987-04-08
NO863974D0 (no) 1986-10-06
NO863974L (no) 1987-04-08
DE3687736D1 (de) 1993-03-25
CA1338706C (en) 1996-11-12
IL80231A (en) 1991-08-16
ATE85652T1 (de) 1993-02-15
DK478886D0 (da) 1986-10-07
AU6356986A (en) 1987-04-09
US4938948A (en) 1990-07-03
EP0220858A2 (en) 1987-05-06
EP0220858A3 (en) 1988-08-03

Similar Documents

Publication Publication Date Title
DK478886A (da) Monoklonalt murinantistof egnet til genkendelse af brysttumorer og immunogenkendelsesmiddel omfattende samme samt fremgangsmaade til genkendelse af samme
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
DK25084A (da) Human-human hybridoma mod neoplasmer
FI853884A7 (fi) Monoklonaaliset, ihmisen rintasyöpää vastaan vaikuttavat vasta-aineet
DE3751908D1 (de) Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
NZ222309A (en) Antibodies (including chimeric antibodies) to a human tumour antigen, polynucleotides encoding them, detection of the antigen by immunoassay and imaging methods and also cell killing methods
DK40885D0 (da) Monoklonalt antistof, fremgangsmaade og celle til fremstilling deraf,fremgangsmaade til fremstilling af cellen og farmaceutisk praeparat indeholdende det monoklonale antistof
EP0597829A4 (en) MONOCLONAL ANTIBODIES AGAINST A NEW ANTIQUE ASSOCIATED WITH HUMAN TUMORS.
DE3887675D1 (de) Antikörper.
ES8506091A1 (es) Un procedimiento para obtener un polidoma
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
DK172686A (da) Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
ES8900247A1 (es) Un metodo de detecion y diagnostico de cancer empleando un nuevo antigeno asociado a un tumor.
DK0387873T3 (da) Anti-humant spermaantistof, fremstilling og anvendelse deraf
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3784364D1 (de) Tumorassoziiertes antigen.
Hand et al. Potential Clinical Application of a Monoclonal Antibody to a Tumor Associated Glycoprotein (TAG-72)
ATE74213T1 (de) Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
JPS6439992A (en) Monoclonal antibody
ATE17190T1 (de) Mittel zur tumorlokalisierung und therapie mit markierten antikoerpern und antikoerperfragmenten.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment